Bioenergetics and Muscle Function Improvement With AMAZ-02 in Elderly Skeletal Muscle (ENERGIZE Trial)

Amazentis

Status: Completed

Conditions: Mitochondrial Function, Bioenergetics; Aging; Muscle Function

Treatments: Dietary Supplement: Placebo; Dietary Supplement: Mitopure

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT03283462

1178231 (Other Identifier)

17.01.AMZ

Details and patient eligibility

About

This is a randomized, double-blind, single-center, placebo-controlled Phase 2 trial enrolling 66 healthy elderly subjects (33 placebo and 33 AMAZ-02 administration) who are ≥65 and ≤ 90 years of age with evidence of low mitochondrial function. AMAZ-02 or placebo will be orally administered for 4 months.

Enrollment: 66 patients

Sex: All

Ages: 65 to 90 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Adults ≥65 and ≤90 years of age
2. Able to travel to and from the University of Washington and Fred Hutch Cancer Research Center (FHCRC)
3. Informed consent obtained
4. 6 minute walk distance of <550 meters
5. ATP max < 1mM /sec (in the hand FDI muscle)

Exclusion criteria

1. Subjects who have significant disease(s) or condition(s) which, in the opinion of the investigator, may put the subject at risk because of their participation in the trial or may influence either the results of the trial or the subject's ability to participate in the trial
2. Hospitalization within 3 months for major atherosclerotic events (defined as combined incidence of myocardial infarction, urgent target-vessel revascularization, coronary bypass surgery and stroke) and for any hospitalization within 2 months.
3. Have any metal implants in the right limbs, including non-MRI compatible metal stents, titanium pins/markers, etc.
4. Have an implanted cardiac pacemaker or other implanted non-MRI compatible cardiac device
5. Chronic, uncontrolled hypertension as judged by the Investigator (i.e., Baseline SBP >150 mm Hg, DBP >90 mm Hg) or a SBP > 150 mm Hg or DBP > 95 mm Hg at the time of screening or baseline. If the initial BP reading is above these values, the reading may be repeated one time within 20 minutes of the initial reading.
6. Body mass index <18 or >32 kg/m2
7. Severe chronic kidney disease requiring treatment with hemodialysis or peritoneal dialysis.
8. Additional laboratory abnormalities determined as clinically significant by the Investigator.
9. Clinically significant abnormalities on physical examination (as judged by the Investigator)
10. Clinically significant and chronic uncontrolled renal, hepatic, pulmonary, endocrine, neurologic disorders, bone, or gastrointestinal system dysfunction
11. History of seizures or epilepsy
12. History of serious mental illness as judged by the Investigator
13. Oral temperature >37.5°C at the time of the physical
14. Suspicion, or recent history, of alcohol or substance abuse or tobacco use
15. Subjects who in the opinion of the Investigator have a clinically significant abnormal 12-lead ECG during the screening period. Presence of atrial fibrillation, varying degrees of AV block, existence of a left bundle branch block, or evidence of previous myocardial infarction.
16. Subjects who are either unwilling to agree to refrain from using or are found to be using supplementary antioxidant vitamins (e.g., Coenzyme Q10, resveratrol, L-carnitine) from 7 days prior to dosing and throughout the treatment period
17. Subjects who are either unwilling to agree to refrain from using or are found to be using the following dietary restrictions (pomegranate juice, walnuts, pecans, strawberry, raspberry blackberry) from 7 days prior to dosing and throughout the treatment period
18. Are currently enrolled in a clinical trial involving an investigational product or non-approved use of a drug or device or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
19. Have participated, within the last 30 days from a clinical trial involving an investigational product. If the previous investigational product has a long half life, 3 months or 5 half-lives (whichever is longer) should have passed

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

66 participants in 2 patient groups, including a placebo group

Mitopure

Active Comparator group

Treatment:

Dietary Supplement: Mitopure

Placebo

Placebo Comparator group

Treatment:

Dietary Supplement: Placebo